Invention Grant
- Patent Title: Antisense oligonucleotides targeting alpha-synuclein and uses thereof
-
Application No.: US16961624Application Date: 2019-01-11
-
Publication No.: US11447775B2Publication Date: 2022-09-20
- Inventor: Richard E. Olson , Angela M. Cacace , Jere E. Meredith, Jr. , Nino Devidze , James K. Loy , Carl J. Baldick , Annapurna Pendri , Ivar M. McDonald , Peter Hagedorn , Marianne Lerbech Jensen
- Applicant: Bristol-Myers Squibb Company , Roche Innovation Center Copenhagen A/S
- Applicant Address: US NJ Princeton; DK Hørsholm
- Assignee: Bristol-Myers Squibb Company,Roche Innovation Center Copenhagen A/S
- Current Assignee: Bristol-Myers Squibb Company,Roche Innovation Center Copenhagen A/S
- Current Assignee Address: US NJ Princeton; DK Hørsholm
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- International Application: PCT/US2019/013249 WO 20190111
- International Announcement: WO2019/140231 WO 20190718
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C12N15/113
Abstract:
The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
Information query
